登录新浪财经APP 搜索【信披】查看更多考评等级 一、 主要财务数据 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或重大遗漏，并承担个别和连带的法律责任。 （一） 主要会计数据和财务指标 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第三季度财务报表是否经审计 证券代码：600568 证券简称：ST中珠 □是 √否 （二） 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 （三） 主要会计数据、财务指标发生变动的情况、原因 √适用 □不适用 二、 股东信息 （一） 普通股股 ...

Financial Data and Key Metrics Changes - In Q3 2025, the company reported net operating revenues of $5.3 billion, with consolidated adjusted EBITDA growing 12% year-over-year to $1.1 billion, resulting in an adjusted EBITDA margin of 20.8%, a 170 basis points improvement from the previous year [5][11] - The company raised its full-year 2025 adjusted EBITDA guidance to a range of $4.47 billion to $4.57 billion, reflecting an increase of $445 million or 11% at the midpoint from initial guidance [7][15] - Free cash flow for Q3 was $778 million, totaling $2.16 billion year-to-date, which is a 22% increase over the same period last year [14] Business Line Data and Key Metrics Changes - The USPI segment generated $492 million in adjusted EBITDA, representing a 12% year-over-year growth, with same-facility revenues increasing by 8.3% [5][11] - The hospital segment's adjusted EBITDA grew 13% to $607 million, with same-store hospital admissions up 1.4% and revenue per adjusted admission increasing by 5.9% [6][12] Market Data and Key Metrics Changes - The company opened a new hospital facility in Port St. Lucie, Florida, aimed at expanding capacity in a rapidly growing area [6] - Exchange business accounted for 8.4% of total admissions and 7% of total consolidated revenues in Q3, showing a slight increase from Q2 [24][77] Company Strategy and Development Direction - The company is focusing on higher acuity services, which has led to improved margins and strong earnings growth [9] - The strategy includes continued M&A and de novo development, with a robust pipeline for future acquisitions [6][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's performance, citing healthy patient demand and stable operating conditions for 2026 [8][9] - There is uncertainty regarding enhanced premium tax subsidies and their impact on reimbursement and enrollment in exchanges, but management is prepared for various scenarios [8][9] Other Important Information - The company has invested nearly $300 million in M&A activities year-to-date and plans to continue this trend [6] - The company has no significant debt maturities until 2027, providing financial flexibility [14] Q&A Session Summary Question: Q4 guidance and utilization expectations - Management has not built in expectations for higher utilization due to exchange subsidies expiring, and they are confident in their capacity to meet typical demand [19][21] Question: CapEx inputs and allocation - The increase in CapEx is focused on clinical program infrastructure and high-acuity service offerings, with specific investments in cardiac care and surgical programs [26][28] Question: Free cash flow sustainability - Management highlighted improved cash collections and operational efficiencies as key drivers of free cash flow, emphasizing a focus on sustainability [30][32] Question: USPI Q4 guidance and growth - The implied Q4 guidance for USPI suggests year-over-year growth of over 8%, which is consistent with historical trends [35][36] Question: Labor environment and inflationary pressures - The labor environment remains strong, and management does not foresee significant changes or inflationary pressures impacting operations in 2026 [39][41] Question: Conifer's contribution and enrollment capabilities - Conifer is performing well, assisting with patient eligibility and enrollment, and is prepared to support potential changes in exchange enrollment timelines [45][47] Question: Service line performance in Q3 - Growth in USPI was driven by higher acuity services, with a noted recovery in GI services, while respiratory and infectious disease volumes were lower than expected [51][53] Question: DPP contribution and estimates for 2026 - The company recorded approximately $346 million in supplemental Medicaid programs in Q3, with $148 million being prior year adjustments [59][60] Question: Capital allocation and buyback strategy - The company remains active in share repurchases and is responsive to market conditions while continuing to pursue M&A opportunities [62][64] Question: Expense management and AI initiatives - The company is exploring opportunities for cost savings and efficiency improvements, including the use of advanced analytics and automation [66][68] Question: M&A environment for ASCs - The company continues to be a partner of choice in the ASC market, focusing on high-end specialties and maintaining a strong pipeline for growth [71][73]

Financial Data and Key Metrics Changes - The company reported a significant increase in inpatient admissions year over year, leading the peer group in growth [20][21] - Adjusted EBITDAR margins improved to over 12% in Q2, a 200 basis point increase from the previous year [48][49] - The company expects to achieve mid-teens margins, comparable to peers, through ongoing margin improvement initiatives [48][49] Business Line Data and Key Metrics Changes - Inpatient surgeries increased by approximately 7% in Q2, indicating the effectiveness of the company's service line rationalization strategy [23][24] - The company is focusing on expanding outpatient services, including urgent care and ambulatory surgery centers, to enhance access points for patients [6][74] - The company has added 18 urgent care facilities this year, with a significant portion of patients being new to the system [27][72] Market Data and Key Metrics Changes - The company operates in eight markets across six states, primarily in the South Central region, with these markets growing at an average rate three times faster than the U.S. average [5][16] - The competitive landscape primarily consists of local and regional nonprofits, with limited competition from for-profit peers [16][17] Company Strategy and Development Direction - The company's growth strategy focuses on deepening its presence in existing markets and expanding outpatient services to create a comprehensive care ecosystem [6][7] - The differentiated joint venture model with nonprofit and academic partners is a key aspect of the company's strategy, enhancing service offerings and operational efficiency [9][10] - The company is exploring opportunities for hospital M&A, particularly in non-expansion states, to further its growth objectives [78][80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for services, attributing strong inpatient volume growth to an aging and sicker population [33][34] - The company is proactively addressing potential reimbursement changes and is optimistic about maintaining growth despite anticipated challenges [67][69] - Management highlighted the importance of technology and innovation in improving operational efficiency and patient care [42][51] Other Important Information - The company is experiencing a stabilization in labor costs, with a focus on improving workplace culture to retain staff [39][40] - There has been a notable increase in denial rates, but efforts are being made to manage and reduce these levels [34][35] Q&A Session Summary Question: What are the highlights from the first half of the year? - The company reported robust volume growth, particularly in inpatient admissions, and a focus on efficiency improvements [20][21] Question: How does the company view the slower volume growth in adjusted admissions? - Management attributed the lower adjusted admissions to a focus on higher acuity inpatient cases and ongoing development of outpatient assets [25][26] Question: What is the company's strategy regarding outpatient services? - The company is prioritizing the expansion of urgent care and ambulatory surgery centers, viewing them as high-return investments [71][74] Question: How is the company addressing denial rates? - Management noted that while initial denials have increased, final denials are stabilizing, indicating effective management efforts [34][35] Question: What is the outlook for Medicaid supplemental payments? - The company anticipates a manageable impact from potential reductions in Medicaid payments, with confidence in continued growth [66][67]

Core Viewpoint - Far East Horizon's 1H25 performance met expectations with a revenue decline of 4% year-on-year to 17.34 billion yuan and a net profit increase of 4% year-on-year to 2.16 billion yuan, resulting in an annualized ROE increase of 17 percentage points to 8.66% [1] Financial Performance - The company's financial business revenue increased by 2% year-on-year to 11.09 billion yuan, accounting for 64% of total revenue, with interest income slightly down by 0.4% to 10.66 billion yuan and consulting fee income up by 167% to 430 million yuan [1] - The net interest margin expanded with net interest spread and net interest margin increasing by 11 basis points and 4 basis points to 4.06% and 4.51% respectively, while asset quality remained stable with a non-performing loan ratio of 1.05% [1] Dividend Policy - The company increased its interim dividend payout ratio by 4 percentage points year-on-year to 50%, maintaining a dividend per share (DPS) of 0.25 HKD, indicating a strong dividend yield despite slower growth in DPS compared to profit growth due to dilution from convertible bonds [1] Industry Operations - The company's industrial operations revenue decreased by 13% year-on-year to 6.33 billion yuan, with a decline in domestic business offset by rapid growth in overseas operations [1] - The healthcare segment saw a revenue decline of 15% year-on-year to 1.8 billion yuan, with net profit down by 28% to 110 million yuan, as the company focused on optimizing cost efficiency and expanding non-insurance business [1] Valuation and Forecast - The company maintains its earnings forecast for 25/26e, currently trading at 0.67x/0.63x P/B for 25/26e, with a target price adjustment of 10% to 8.8 HKD, reflecting a significant discount in valuation and attractive dividend expectations [2]

Company Overview - Guangdong Kanghua Medical Group Co., Ltd. was established in 2002 and is a leading private for-profit hospital operator in China, focusing on hospital services, rehabilitation, and pharmaceutical sales [4] - The company operates two general hospitals in Dongguan, namely Kanghua Hospital and Renkang Hospital, and a cardiovascular specialty hospital in Chongqing [4] - Kanghua Hospital is one of the first private for-profit general hospitals in China to receive a three-level A rating from the National Health Commission [4] Financial Performance - As of December 31, 2024, Kanghua Medical achieved total revenue of 2.056 billion yuan, a year-on-year increase of 0.68% [2] - The net profit attributable to shareholders was 15.337 million yuan, a significant decrease of 87.33% year-on-year [2] - The gross profit margin stood at 15.66%, with a debt-to-asset ratio of 46.66% [2] Market Position and Valuation - Currently, there are no institutional investment ratings for Kanghua Medical [3] - The company's price-to-earnings (P/E) ratio is 35.33, ranking 42nd in the healthcare equipment and services industry, which has an average P/E ratio of -2.12 [3] - Other companies in the industry have significantly lower P/E ratios, such as Giant Medical Holdings at 0.37 and Jingjiu Medical at 0.38 [3] Strategic Focus - The company aims to enhance its core medical competencies and promote the development of specialized medical fields, thereby improving diagnostic capabilities and inter-disciplinary collaboration [4] - Kanghua Medical has expanded its influence in the private healthcare sector in China through strategic acquisitions, including the purchase of Anhui Hualin Rehabilitation Medical Group [4] - Future plans include optimizing medical resource allocation and accelerating the expansion of its medical network in the Chinese healthcare market [4]